Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02001623 · ClinicalTrials.gov registry record · Phase 1
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
A Phase 1 study, sponsored by Seagen.
- Completed
- Registry status
- Phase 1
- Development phase
- 195
- Enrollment target
NCT02001623 is a Phase 1 study that has completed, run by Seagen. The registered enrollment target is 195 participants.
The verdict
NCT02001623, a Phase 1 study, has completed, sponsored by Seagen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 195 participants
- Enrollment target
Study Summary
The purpose of the trial is to establish the tolerability of HuMax-TF-ADC in a mixed population of patients with specified solid tumors.
Interventions
- DRUG Tisotumab Vedotin (HuMax-TF-ADC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 195 participants |
| Start Date | 2013-11-30 |
| Est. Completion | 2019-05-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02001623
The ClinicalTrials.gov registry entry for NCT02001623 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 195 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, which has 84 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tisotumab Vedotin (HuMax-TF-ADC) is the first listed.
NCT02001623 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02001623 about?
NCT02001623 is a clinical study titled "Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors". The purpose of the trial is to establish the tolerability of HuMax-TF-ADC in a mixed population of patients with specified solid tumors.
What is the current status of trial NCT02001623?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 195 participants. The study started on 2013-11-30. Estimated completion is 2019-05-02.
What interventions are being tested in trial NCT02001623?
The interventions under investigation include: Tisotumab Vedotin (HuMax-TF-ADC) (DRUG).
Who is sponsoring clinical trial NCT02001623?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.